Study Title and Description
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
Key Questions Addressed
|6||Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?|
|7||Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?|
|8||Key Question 8. What are the harms of currently recommended antiviral treatments?|
Primary Publication Information
|Title||Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.|
|Author||Abergel A., Metivier S., Samuel D., Jiang D., Kersey K., Pang PS., Svarovskaia E., Knox SJ., Loustaud-Ratti V., Asselah T.|
|Country||Department of Hepatology and Gastroenterology, Centre Hospitalier Universitaire Estaing, Université d'Auvergne, UMR CNRS 6284, Clermont-Ferrand, France. email@example.com.|
Pubmed ID: 27351341
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.